Dr. Samadi’s Prostate Cancer Center Will Offer Patients a Revolutionary Platform of Genetic Testing

Dr. Samadi’s Prostate Cancer Center Will Offer Patients a Revolutionary Platform of Genetic Testing
This week Dr. Samadi's Prostate Cancer Center announced that it is now offering a range of genetic tests that will assess a patient’s risk for prostate cancer (PC), as well as, more effectively diagnosis disease, both pre-biopsy and post-biopsy. Background Terminology:
  • Prostate-specific antigen (PSA): is a substance produced by the prostate gland. Elevated PSA levels may indicate prostate cancer, a noncancerous condition such as prostatitis, or an enlarged prostate.
  • Biomarkers: short for biological markers, are the measures used to perform a clinical assessment- examples include blood pressure or PSA levels, that are used to monitor and predict patient’s health status
Dr. David B. Samadi, MD, is a board certified urologic oncologist trained in open traditional and laparoscopic surgery and is an expert in robotic prostate surgery. He is Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital, Professor of Urology at Hofstra North Shore-LIJ School of Medicine. He has dedicated his distinguished career to the early detection, diagnosis and treatment of prostate cancer and is considered one of the most prominent surgeons in his field. In the announcement press release, Dr. Samadi stated, "We're very excited to now offer these revolutionary genetic tests to men with an elevated PSA or after a biopsy. Thanks to these
Subscribe or to access all post and page content.